Table 3.
Prognostic factors for recurrence and progression in 130 patients with NMIBC
| Variables | Intravesical recurrence‐free survival | Progression‐free survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariatea | Univariate | Multivariatea | |||||||||
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| Age (years) | ||||||||||||
| ≥70/<70 | 1.39 | 0.73–2.66 | 0.34 | NA | 6.70 | 2.09–21.5 | 0.035 | 3.35 | 0.74–15.1 | 0.12 | ||
| Sex | ||||||||||||
| Female/Male | 1.27 | 0.45–3.54 | 0.62 | NA | 3.83 | 0.65–22.5 | 0.018 | 3.57 | 0.95–13.3 | 0.06 | ||
| T stage | ||||||||||||
| T1 or isolated Tis/Ta | 1.64 | 0.85–3.36 | 0.12 | NA | 9.44 | 2.87–31.1 | 0.0002 | 5.58 | 1.51–20.6 | 0.01 | ||
| Tumor grade | ||||||||||||
| High/Low | 1.73 | 0.91–3.30 | 0.083 | 0.99 | 0.47–2.07 | 0.97 | 9.64 | 3.08–30.2 | 0.0002 | 0.89 | 0.62–12.5 | 0.93 |
| Multiplicity | ||||||||||||
| Multiple/Solitary | 1.63 | 0.86–3.08 | 0.14 | NA | 2.49 | 0.76–8.12 | 0.16 | NA | ||||
| Carcinoma in situ | ||||||||||||
| Yes/No | 1.60 | 0.79–3.23 | 0.14 | NA | 6.67 | 1.96–22.7 | 0.001 | 1.92 | 0.50–7.28 | 0.35 | ||
| COL4A1 (ng/mL) | ||||||||||||
| ≥2.76/<2.76 | 3.26 | 1.71–6.23 | 0.002 | NA | 5.00 | 1.52–16.2 | 0.023 | NA | ||||
| COL13A1 (ng/mL) | ||||||||||||
| ≥0.45/<0.45 | 2.64 | 1.38–5.03 | 0.005 | NA | 2.79 | 0.85–9.10 | 0.11 | NA | ||||
| No. high COL | ||||||||||||
| 1/0 | 2.39 | 0.84–6.75 | 0.11 | NA | 3.48 | 1.08–11.3 | 0.047 | NA | ||||
| 2/0 | 2.91 | 1.44–8.28 | 0.008 | NA | 4.32 | 1.27–15.2 | 0.04 | NA | ||||
| COL4A1 + COL13A1 (ng/mL) | ||||||||||||
| ≥3.40/<3.40 | 3.10 | 1.61–5.87 | 0.001 | 2.13 | 1.11–7.11 | 0.029 | 5.06 | 1.55–16.5 | 0.021 | 1.97 | 0.48–8.10 | 0.24 |
| CYFRA21‐1 (ng/mL) | ||||||||||||
| ≥4.06/<4.06 | 3.42 | 1.74–6.72 | 0.0007 | 2.12 | 0.91–4.97 | 0.083 | 2.78 | 0.85–9.07 | 0.11 | NA | ||
| NMP‐22 (U/mL) | ||||||||||||
| ≥6.36/<6.36 | 1.58 | 0.83–3.01 | 0.16 | NA | 2.88 | 0.88–9.41 | 0.10 | NA | ||||
a
Treatment‐adjusted multivariate Cox regression analysis; CI, confidence interval; COL, collagen; COL13A1, collagen type 13 alpha 1; COL4A1, collagen type 4 alpha 1; CYFRA21‐1, fragments of cytokeratin‐19; HR, hazard ratio; NA, not analyzed; NMIBC, non‐muscle invasive BCa; NMP‐22, nuclear matrix protein 22.